

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



創美·CH'MEI

**CHARMACY PHARMACEUTICAL CO., LTD.**

創美藥業股份有限公司

*(A joint stock limited liability company established in the People's Republic of China)*

**(Stock Code: 2289)**

**INSIDE INFORMATION**  
**APPROVAL BY THE CSRC OF THE APPLICATION**  
**FOR H SHARE FULL CIRCULATION PROGRAMME OF THE COMPANY**

This announcement is made by Charmacy Pharmaceutical Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 15 February 2022 in relation to the proposed participation in the H share full circulation programme by the Company.

The Company is pleased to announce that on 6 June 2022, a formal approval (the “**Approval**”) from China Securities Regulatory Commission (the “**CSRC**”) on the application submitted by the Company to the CSRC regarding the implementation of H share full circulation programme of the Company has been received by the Company, pursuant to which Mr. Yao Chuanglong (姚創龍先生), Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd.\* (江西江中醫藥商業運營有限責任公司), Shantou Meizhi Investment Management Limited Partnership\* (汕頭市美智投資管理合夥企業(有限合夥)), Shantou Youran Investment Management Limited Partnership\* (汕頭市悠然投資管理合夥企業(有限合夥)) and Shantou Zhichuang Investment Management Limited Partnership\* (汕頭市智創投資管理合夥企業(有限合夥)), the domestic shareholders of the Company are allowed to convert up to an aggregate of 80 million unlisted domestic shares of the Company into H shares of the Company and the listing thereof on the main board of the Stock Exchange (the “**Conversion and Listing**”). The Approval shall be valid for 12 months from 31 May 2022.

As at the date of this announcement, the details of implementation plan of the Conversion and Listing have not been finalised. The Company will make further announcements on the progress of the Conversion and Listing in compliance with the requirements under Listing Rules and the applicable laws, as and when appropriate.

**The Conversion and Listing is still subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other domestic and foreign regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yao Chuanglong**  
*Chairman*

Shantou, the PRC, 6 June 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong and Ms. Zheng Yuyan; the non-executive directors of the Company are Mr. Li Weisheng and Mr. Yan Jingbin; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).*

*\* For identification purpose only*